962.27
+3.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About argenx NV ADR
Its shares trade under the ticker ARGX. It has been listed since 18 May 2017. In the fiscal year to 31 December 2025, it reported revenue of $4.15bn and net income of $1.29bn. At that date it held total assets of $8.68bn and shareholders' equity of $7.32bn.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 May 2017
- Employees
- 1,863
- Website
- argenx.com ↗
- Head office
- INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE
- Incorporated in
- P7
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- argenx NV ADR has a strong presence in the US, Japan, China, and the Netherlands for autoimmune disease therapies.
- VYVGART and VYVGART HYTRULO are approved treatments for gMG and ITP in multiple countries.
- The company's pipeline includes ARGX-213, ARGX-124, and ARGX-109 targeting various autoimmune conditions.
Weaknesses
- argenx NV ADR's business is concentrated in the Health Care sector with limited diversification.
- The company relies on partnerships with Zai Lab for development of certain therapies.
- argenx NV ADR has a relatively small employee count of 1863 compared to larger biopharma firms.
Opportunities
- Expanding VYVGART HYTRULO for new indications like CIDP and MMN in the US market.
- Growing demand for autoimmune disease treatments in China and Japan markets.
- Strategic partnerships with Zai Lab could lead to new therapy developments in Asia.
Threats
- Regulatory challenges in the US and Japan for new autoimmune therapies.
- Competition from other biopharma companies in the Health Care sector.
- Potential delays in clinical trials for ARGX-118 and other pipeline candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.